CUE.O (CUE.O) News
Track canonical SquawkNews coverage tagged to CUE.O, CUE.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BRIEF — Cue Biopharma Announces Positive Topline Results From Cue — 221 Phase 2 Study In Chronic Spontaneous Urticaria
Sept 20 (Reuters) — Cue Biopharma, Inc.: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria Cue Biopharma, - Phase 2 Primary And Key Secondary Endpoints Met Sourc
NEWS | Sep 20, 2026, 10:07 AM UTC
L
Cue Biopharma says CUE — 221 Phase 2 trial in chronic spontaneous urticaria meets primary endpoint
Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, meeting primary and key secondary goals. Responses strengthened beyond the main assessment window, with benefit persis
NEWS | Sep 20, 2026, 10:02 AM UTC